Simplify Asset Management Inc. acquired a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 120,000 shares of the company's stock, valued at approximately $833,000. Simplify Asset Management Inc. owned approximately 0.23% of Zevra Therapeutics as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of the company. City State Bank lifted its holdings in shares of Zevra Therapeutics by 14.1% in the third quarter. City State Bank now owns 16,224 shares of the company's stock worth $113,000 after acquiring an additional 2,000 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Zevra Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company's stock worth $91,000 after acquiring an additional 2,452 shares during the last quarter. International Assets Investment Management LLC raised its holdings in Zevra Therapeutics by 594.0% in the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company's stock valued at $48,000 after buying an additional 5,940 shares during the last quarter. IFG Advisors LLC raised its holdings in Zevra Therapeutics by 41.2% in the 3rd quarter. IFG Advisors LLC now owns 26,400 shares of the company's stock valued at $183,000 after buying an additional 7,700 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in Zevra Therapeutics by 17.9% in the 2nd quarter. Rhumbline Advisers now owns 56,874 shares of the company's stock valued at $279,000 after buying an additional 8,619 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.
Zevra Therapeutics Trading Down 4.5 %
Shares of ZVRA stock traded down $0.41 during trading hours on Friday, hitting $8.62. 1,369,032 shares of the company were exchanged, compared to its average volume of 548,353. The firm has a market cap of $453.57 million, a P/E ratio of -4.38 and a beta of 1.93. Zevra Therapeutics, Inc. has a fifty-two week low of $4.18 and a fifty-two week high of $9.21. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00. The company has a 50 day simple moving average of $8.03 and a two-hundred day simple moving average of $6.49.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 177.96%. The business had revenue of $4.45 million during the quarter, compared to analyst estimates of $4.08 million. During the same period in the previous year, the business posted ($0.15) EPS. Equities analysts anticipate that Zevra Therapeutics, Inc. will post -1.63 EPS for the current year.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zevra Therapeutics in a report on Friday, October 11th. Roth Mkm increased their target price on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a "buy" rating in a research report on Tuesday, September 24th. HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Zevra Therapeutics in a research report on Monday, September 30th. Guggenheim started coverage on shares of Zevra Therapeutics in a research report on Monday, October 7th. They set a "buy" rating and a $20.00 target price for the company. Finally, Maxim Group increased their target price on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday, September 24th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Zevra Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $21.00.
Read Our Latest Analysis on ZVRA
About Zevra Therapeutics
(
Free Report)
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
Further Reading
Before you consider Zevra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.
While Zevra Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
